Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone diacetate
Drug ID BADD_D02273
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00984
MeSH ID C030262
PubChem ID 6216
TTD Drug ID Not Available
NDC Product Code 38779-0166; 46439-8766; 52128-171; 62991-2175; 49452-7910
Synonyms triamcinolone diacetate | Polcartolone | Polcortolon
Chemical Information
Molecular Formula C25H31FO8
CAS Registry Number 67-78-7
SMILES CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osteoporosis15.02.03.002; 14.04.04.002--
Pancreatitis07.18.01.001--
Papilloedema17.07.02.004; 06.09.02.002; 24.03.07.001--
Paraesthesia17.02.06.005--
Paraparesis17.01.04.006--Not Available
Paraplegia17.01.04.007--Not Available
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Peptic ulcer07.04.07.001--Not Available
Personality change19.05.01.006; 17.02.05.019--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Secondary adrenocortical insufficiency05.01.02.003; 14.11.01.014--Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.006--Not Available
Skin atrophy23.01.05.001--
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.003--
Spermatozoa abnormal13.20.01.005--Not Available
Spinal fracture15.08.05.001; 12.04.04.002--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Thrombophlebitis24.01.02.001--Not Available
Vasculitis10.02.02.006; 24.05.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Weight increased13.15.01.006--
Oesophagitis ulcerative07.04.05.003--Not Available
Growth retardation15.03.01.006--
Affect lability19.04.01.001--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages